Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417113 · ClinicalTrials.gov registry record · Phase 4
Erector Spinae Block for Spine Surgery
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT05417113 is a Phase 4 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 13 participants.
The verdict
NCT05417113, a Phase 4 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is to determine whether or not the addition of liposomal bupivacaine in an ESP block will have long term benefits for patients undergoing lumbar spinal fusion surgery. Given previous studies found long term benefits from liposomal bupivacaine, the hypothesis is that patients will have decreased opioid usage and improved pain scores when compared to a standard ESP block with plain 0.25% bupivacaine.
Interventions
- DRUG Bupivacaine
- DRUG Liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05417113
The ClinicalTrials.gov registry entry for NCT05417113 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT05417113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05417113 about?
NCT05417113 is a clinical study titled "Erector Spinae Block for Spine Surgery". This study is to determine whether or not the addition of liposomal bupivacaine in an ESP block will have long term benefits for patients undergoing lumbar spinal fusion surgery. Given previous studies found long term benefits from liposomal bupivacaine, the hypothesis is that patients will have dec...
What is the current status of trial NCT05417113?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2022-08-31. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT05417113?
The interventions under investigation include: Bupivacaine (DRUG), Liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT05417113?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.